Answers are grounded in this paper and cite their sources.
Retrospective study finds similar remission rates between venetoclax-azacitidine and cytarabine salvage in relapsed acute myeloid leukemia, suggesting age and cytogenetics should guide selection.
Summary Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)‐dose cytarabine (DAC) ( n = 203) and venetoclax‐azacitidine (VEN‐AZA) ( n = 114) for patients with AML in first relapse. Patients (median age 60 years, interquartile range [IQR] 48–67) had reached CR1 after a standard 7 + 3 ( n = 305) or CPX351 schedule ( n = 12). I/HDAC‐based and VEN‐AZA salvage, respectively, resulted in CR2 in 66.0% and 66.7% of the patients ( p = 0.96). Allogeneic haematopoietic stem cell transplantation (allo‐HSCT) was performed for 115 patients in CR2 and 18 in failure. Relapse‐free survival was 13.2 (IQR 7.0‐not reached [NR]) and 13.7 (IQR 7.8‐NR) months while overall survival (OS) was 14.5 (IQR 6.2‐NR) and 12.3 months (IQR 4.8‐NR; p = 0.41) for patients who received I/HDAC‐based salvage and VEN‐AZA respectively. In multivariable analysis, relapsing patients ≥60 years with low/intermediate‐risk cytogenetics and VEN‐AZA had a better OS ( p = 0.002), while I/HDAC was more efficient for those with poor risk cytogenetics and < 60‐year‐old ( p = 0.002). VEN‐AZA salvage therapy thus appears promising compared with conventional I/HDAC‐based IC; this question warrants evaluation in randomized studies.
No takes yet. Share an insight, caveat, or question.
Dumas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: